<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ke ZH</submitter><funding>The National Natural Science Foundation of China</funding><funding>The Zhejiang Provincial Medical and Health Science and Technology Plan</funding><pagination>e70486</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11632276</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(23)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Immune biomarkers for non-small-cell lung cancer (NSCLC) are programmed death ligand 1 (PD-L1) and tumor mutational burden (TMB). However, they cannot accurately predict the effectiveness of immunotherapy. Identifying appropriate biomarkers that can differentiate between beneficiary groups is imperative.&lt;h4>Methods&lt;/h4>We identified lipoprotein receptor-related protein 1B (LRP1B) mutation as a potential biomarker for immunotherapy by analyzing clinical data, combined with bioinformatics analysis. The effects of LRP1B on ferroptosis were assessed using qRT-PCR, Western blotting, CCK-8 assay, and flow cytometry. The potential mechanism underlying the regulation of ferroptosis by LRP1B was elucidated using qRT-PCR, Western blotting, ChIP, and dual-luciferase reporter gene a</pubmed_abstract><journal>Cancer medicine</journal><pubmed_title>LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis.</pubmed_title><pmcid>PMC11632276</pmcid><funding_grant_id>82172708</funding_grant_id><funding_grant_id>2024KY1517</funding_grant_id><funding_grant_id>82300230</funding_grant_id><pubmed_authors>Lu KH</pubmed_authors><pubmed_authors>Xiang Y</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Yu T</pubmed_authors><pubmed_authors>Ke ZH</pubmed_authors><pubmed_authors>Zhang Q</pubmed_authors></additional><is_claimable>false</is_claimable><name>LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis.</name><description>&lt;h4>Background&lt;/h4>Immune biomarkers for non-small-cell lung cancer (NSCLC) are programmed death ligand 1 (PD-L1) and tumor mutational burden (TMB). However, they cannot accurately predict the effectiveness of immunotherapy. Identifying appropriate biomarkers that can differentiate between beneficiary groups is imperative.&lt;h4>Methods&lt;/h4>We identified lipoprotein receptor-related protein 1B (LRP1B) mutation as a potential biomarker for immunotherapy by analyzing clinical data, combined with bioinformatics analysis. The effects of LRP1B on ferroptosis were assessed using qRT-PCR, Western blotting, CCK-8 assay, and flow cytometry. The potential mechanism underlying the regulation of ferroptosis by LRP1B was elucidated using qRT-PCR, Western blotting, ChIP, and dual-luciferase reporter gene a</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2025-04-26T16:07:47.171Z</modification><creation>2025-04-06T15:10:24.912Z</creation></dates><accession>S-EPMC11632276</accession><cross_references><pubmed>39660409</pubmed><doi>10.1002/cam4.70486</doi></cross_references></HashMap>